Centre for Biotechnology and Bioinformatics (CEBIB), University of Nairobi
F.A. Meyers Adrienne
Department of Medical Microbiology, University of Manitoba – Winnipeg; Department of Medical Microbiology, University of Nairobi; National Laboratory for HIV Immunology, Public Health Agency of Canada
J. Kimani
Department of Medical Microbiology, University of Nairobi
T.B. Ball
Department of Medical Microbiology, University of Manitoba – Winnipeg; Department of Medical Microbiology, University of Nairobi; National Laboratory for HIV Immunology, Public Health Agency of Canada
E. Songok
Department of Medical Microbiology, University of Manitoba – Winnipeg; Kenya Medical Research Institute (KEMRI) – Nairobi
Main Article Content
Drug resistance mutations among antiretroviral-treated female sex workers in Nairobi, Kenya
C. Meeme
F.A. Meyers Adrienne
J. Kimani
T.B. Ball
E. Songok
Abstract
Antiretroviral drug resistance remains an important and a growing challenge in HIV management as it almost always lead to treatment failure. Sex workers face persistent exposures to the different HIV-1 variants and in turn pose a risk of transmission to the general population and measuring drug resistance in this population may serve as a measure for the risk of transmission of these strains to drug naïve populations. The objective of this study was therefore to determine the pattern and prevalence of HIV-1 drug resistance mutations in a cohort of female sex workers in Nairobi, Kenya. Plasma from 60 female sex workers on antiretroviral treatment for over six months was analyzed by amplification and sequencing of the reverse transcriptase - pol region. Five samples (8.3%) showed antiretroviral resistance-associated mutations. One sample (1.7%) showed mutations conferring resistance only to the NNRTI class, 2 samples (3.3%) showed mutations conferring resistance only to the NRTI class while 2 samples (3.3%) showed mutations conferring resistance to both NRTI and NNRTI classes. Phylogenetic analysis revealed HIV-1 subtype A1 (96.7%) and HIV-1 subtype D (3.3%). The prevalence rate of 8.3% for reverse transcriptase-associated resistance mutations was observed. This is a lower rate than has been reported from studies among antiretroviral (ARV)-treated individuals in the country.
Afr J Health Sci. 2013; 26:291-302
Donate
AJOL is a Non Profit Organisation that cannot function without donations.
AJOL and the millions of African and international researchers who rely on our free services are deeply grateful for your contribution.
AJOL is annually audited and was also independently assessed in 2019 by E&Y.
Your donation is guaranteed to directly contribute to Africans sharing their research output with a global readership.
Once off donations here:
For annual AJOL Supporter contributions, please view our Supporters page.
Tell us what you think and showcase the impact of your research!
Please take 5 minutes to contribute to our survey so that we can better understand the contribution that African research makes to global and African development challenges. Share your feedback to help us make sure that AJOL's services support and amplify the voices of researchers like you.